XML 71 R59.htm IDEA: XBRL DOCUMENT v3.25.2
Investments Accounted for Using the Equity Method - Summary of Principal Transactions and Balances with Related Parties (Details) - EUR (€)
€ in Millions
 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Oct. 31, 2024
Disclosure of transactions between related parties [line items]        
Other Assets, Related Party Transactions € 189   € 189  
Subordinate Hybrid Bond, Related Party Transactions       € 200
Associates and joint ventures        
Disclosure of transactions between related parties [line items]        
Sales (c) (d) [1],[2] 29 € 59    
Royalties and other income (c) (d) [1],[2] 63 33    
Amounts receivable, related party transactions [3] 299   184  
Other Assets, Related Party Transactions [4] 189   189  
Purchases of goods and services (including research expenses) (c) (d) [1],[2] 371 € 333    
Amounts payable, related party transactions € 637   € 160  
[1]
(c)    Figures for 2024 comparative periods have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[2]
(d) For the six months ended June 30, 2025, these amounts include transactions between Sanofi and OPAL JV Co for the period from May 1, 2025 through June 30, 2025.
[3]
(a)    Includes loans to joint ventures and associates.
[4]
(b)    In October 2024, Sanofi raised its investment in EUROAPI by €200 million in the form of a perpetual subordinated hybrid bond. The fair value of this investment as of June 30, 2025 was €189 million (and was also €189 million as of December 31, 2024).